Anti-amyloid-β Monoclonal Antibodies

Anti-amyloid-β monoclonal antibodies are disease-modifying therapies designed to remove aggregated amyloid-β from the brain in people with early symptomatic Alzheimer’s disease. Lecanemab received traditional U.S. FDA approval in 2023 after a randomized phase 3 trial showed a statistically significant slowing of clinical decline, while donanemab received U.S. FDA approval in 2024 following a phase 3 trial with similar disease-modification objectives. Their use depends on confirmed amyloid pathology, careful staging, infusion capacity, adverse-event monitoring, and magnetic-resonance-imaging surveillance for amyloid-related imaging abnormalities (ARIA). The therapeutic class therefore links drug development with diagnostic access, specialist expertise, radiology, genetics, and long-term care coordination.

The Alzheimer’s treatment landscape is shifting from predominantly symptomatic management toward biomarker-confirmed interventions intended to slow progression. This transition is supported by amyloid positron-emission tomography, cerebrospinal-fluid testing, and increasingly validated blood-based biomarkers, although test performance, reimbursement, and implementation standards differ across health systems. Clinical adoption is also being reshaped by intravenous administration, treatment-duration decisions, infusion-reaction management, and ARIA risk mitigation. Regulators and clinical organizations continue to emphasize appropriate-patient selection, informed consent, post-marketing surveillance, and equitable access rather than treating amyloid removal as a stand-alone solution.

Artificial intelligence can support this field by improving MRI interpretation, quantifying amyloid burden, identifying subtle cognitive trajectories, and prioritizing patients for confirmatory testing. Machine-learning tools may also assist clinical-trial recruitment, protocol adherence, infusion scheduling, and pharmacovigilance. However, these applications require external validation, representative training data, transparent performance measures, and clinician oversight. AI does not replace biomarker confirmation or regulatory evidence; biased datasets, inconsistent imaging protocols, privacy constraints, and false-positive findings could undermine safe deployment. The most credible near-term role is decision support integrated into established diagnostic and monitoring pathways.

North America has advanced regulatory experience and specialist infrastructure, but access is shaped by coverage rules, diagnostic confirmation, MRI capacity, and genetic risk assessment. Europe is developing implementation pathways through national and European regulatory systems, with substantial variation in reimbursement, memory-clinic capacity, and diagnostic access. Asia-Pacific combines strong research capabilities in countries such as Japan, China, South Korea, and Australia with uneven availability of biomarkers, specialists, and infusion services. Latin America faces constraints in diagnosis, affordability, and specialist distribution, while selected centers are building research capacity. The Middle East is expanding tertiary-care infrastructure but remains heterogeneous in reimbursement and referral pathways. Africa generally requires greater investment in dementia surveillance, specialist training, biomarker access, and health-system capacity before broad deployment can be considered.

ASEAN countries face diverse regulatory systems, healthcare financing models, and specialist availability, making regional harmonization and referral networks particularly relevant. BRICS members combine major academic and clinical capabilities with substantial differences in diagnostic access, reimbursement, and public-health priorities. The European Union benefits from shared scientific and regulatory cooperation, while implementation remains dependent on national health-technology assessment and payment decisions. G7 countries generally possess advanced research, imaging, and pharmacovigilance infrastructure, but must address affordability and capacity constraints. GCC states can leverage concentrated tertiary-care investment and cross-border expertise, although population coverage and national reimbursement policies vary. NATO members span mature and emerging health systems, creating opportunities for common research standards while preserving national authority over clinical adoption.

The United States has established regulatory precedents and broad specialist capacity, with ongoing attention to Medicare coverage, ARIA monitoring, and equitable access. Canada’s implementation depends on provincial assessment, reimbursement, and specialist distribution. The United Kingdom is integrating evidence review with National Health Service capacity planning, while France, Germany, Italy, and Spain must align European authorization with national assessment, payment, memory-clinic capacity, and MRI access. Australia faces geographic dispersion and the need to coordinate diagnosis, infusion delivery, and monitoring. Japan has mature dementia-care infrastructure and a strong clinical-research base; China is expanding Alzheimer’s research and diagnostic capability across a highly varied health system; and South Korea is strengthening biomarker and specialist capacity. India, Brazil, Mexico, and Russia require attention to affordability, diagnostic availability, trained personnel, and regional disparities. Across all countries, APOE ε4 testing, MRI surveillance, infusion safety, and informed consent should be governed by locally appropriate clinical protocols.

Industry leaders should first define an evidence-based pathway that links cognitive staging, amyloid confirmation, MRI eligibility, genetic-risk discussion, and shared decision-making. They should then partner with health systems to expand memory clinics, infusion services, emergency response procedures, and standardized ARIA surveillance. Diagnostic strategies should use validated blood tests only where performance and regulatory status support the intended decision, with confirmatory testing when required. Organizations should establish real-world registries that track effectiveness, discontinuation, adverse events, health disparities, and treatment burden. AI should be deployed as audited clinical decision support, not as an autonomous diagnostic authority. Finally, leaders should engage regulators, payers, clinicians, caregivers, and patient groups early to address reimbursement, workforce training, data governance, and equitable access.

This executive summary is based on triangulation of publicly documented regulatory decisions, randomized clinical-trial evidence, peer-reviewed Alzheimer’s research, clinical-practice guidance, biomarker literature, pharmacovigilance principles, and publicly available health-system information. Findings were organized by therapy characteristics, clinical evidence, diagnostic requirements, safety monitoring, artificial-intelligence applications, geography, and implementation readiness. Regional, group, and country comparisons are qualitative and reflect differences in regulation, reimbursement, infrastructure, specialist capacity, and diagnostic availability. Claims were limited to established or clearly documented developments, and unsupported market estimates, forecasts, company-specific assertions, and market-share statements were excluded.

Anti-amyloid-β monoclonal antibodies represent a meaningful change in Alzheimer’s care because they connect biomarker-defined diagnosis with treatment intended to slow clinical decline. Their practical value will depend on selecting appropriate patients, managing ARIA and infusion risks, ensuring reliable MRI and biomarker access, and integrating treatment into coordinated memory-care pathways. Regional and country differences in regulation, financing, workforce, and infrastructure will shape real-world availability. Sustainable progress therefore requires disciplined evidence generation, transparent safety monitoring, responsible AI adoption, and health-system investment alongside continued therapeutic innovation.